Looking Back at CAR T: PROs From a Patient's Perspective

Article

A survivor of chronic lymphocytic leukemia who participated in the first chimeric antigen receptor T-cell trial in 2010 looks back at his experience and also discusses his views on how patient-reported outcomes (PROs) should be used, if at all, by CMS.

There are 2 approved chimeric antigen receptor (CAR) T-cell therapies on the market for patients with advanced leukemias and lymphomas, Novartis’ tisagenlecleucel (Kymriah) and Kite Pharma/Gilead’s axicabtagene ciloleucel (Yescarta). These immunotherapies are revolutionizing cancer treatment, albeit at great cost.

Doug Olson, a survivor of chronic lymphocytic leukemia, participated in the first CAR T trial in 2010, and joined a recent meeting of the Medicare Evidence Development and Coverage Advisory Committee convened by CMS to discuss how patient-reported outcomes (PROs) should be used, if at all, in any future coverage decisions.

He discussed his experience with CAR T, and his thoughts about PROs and costs, in a podcast after the meeting.

You may need to login to listen to the podcast.

iTunes: http://apple.co/2eYWTss

TuneIn: http://bit.ly/2gv7iwj

Stitcher: http://bit.ly/2gCqtFg

Listen above or through one of these podcast services:

MEDCAC Panel Mostly Endorses PROs for CAR T Therapies

Many Questions to Ask in Setting National Coverage for CAR T Therapies

NCCN Report on CAR T-Cell Therapy, Recommendations for Future Use

With Approval of CAR T-Cell Therapy Comes the Next Challenge: Payer Coverage

Learn more about CAR T:

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.